← Back to Search

Unknown

JV-GL1 for Ocular Hypertension

Phase 1 & 2
Waitlist Available
Led By David Wirta, MD
Research Sponsored by JeniVision, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to day 28 of treatment
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called JV-GL1 to see if it can safely lower eye pressure in adults with open-angle glaucoma or ocular hypertension. By reducing eye pressure, JV-GL1 might help protect vision.

Eligible Conditions
  • Ocular Hypertension
  • Open-Angle Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to day 28 of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to day 28 of treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Intraocular Pressure (IOP)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Randomized Part 2, Arm 2Experimental Treatment1 Intervention
Dose 2 selected in Part I
Group II: Randomized Part 2, Arm 1Experimental Treatment1 Intervention
Dose 1 selected in Part I
Group III: Randomized Part 2, Arm 3Active Control1 Intervention

Find a Location

Who is running the clinical trial?

JeniVision, Inc.Lead Sponsor
David Wirta, MDPrincipal InvestigatorEye Research Foundation, Inc.
3 Previous Clinical Trials
718 Total Patients Enrolled
1 Trials studying Ocular Hypertension
77 Patients Enrolled for Ocular Hypertension
~4 spots leftby Mar 2025